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Abstract
In the United States, more than 40% of cancer patients develop brain metastasis. The median survival for untreated
patients is 1 to 2 months, which may be extended to 6 months with conventional radiotherapy and chemotherapy.
The growth and survival of metastasis depend on the interaction of tumor cells with host factors in the organ mi-
croenvironment. Brain metastases are surrounded and infiltrated by activated astrocytes and are highly resistant to
chemotherapy. We report here that coculture of human breast cancer cells or lung cancer cells with murine astro-
cytes (but not murine fibroblasts) led to the up-regulation of survival genes, including GSTA5, BCL2L1, and TWIST1, in
the tumor cells. The degree of up-regulation directly correlated with increased resistance to all tested chemothera-
peutic agents. We further show that the up-regulation of the survival genes and consequent resistance are depen-
dent on the direct contact between the astrocytes and tumor cells through gap junctions and are therefore transient.
Knocking down these genes with specific small interfering RNA rendered the tumor cells sensitive to chemothera-
peutic agents. These data clearly demonstrate that host cells in the microenvironment influence the biologic behavior
of tumor cells and reinforce the contention that the organ microenvironment must be taken into consideration during
the design of therapy.
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Introduction
In the United States, more than 40% of cancer patients develop brain
metastasis; specifically, nearly 50% of patients with lung cancer, 25%
of patients with breast cancer, and 15% of patients with melanoma
[1–4]. With improved local control and therapy for metastasis to
visceral organs, the morbidity and mortality due to late-diagnosed
brain metastasis are projected to rise [1,4]. The median survival for
untreated patients is 1 to 2 months, which may be extended to
6 months with conventional radiotherapy and chemotherapy [1,4].
The resistance of tumor cells growing in the brain parenchyma to
chemotherapy has been attributed to the inability of circulating che-
motherapeutic drugs to penetrate the blood-brain barrier (BBB),
which is composed of brain endothelial cells with tight junctions
enwrapped with basement membrane, pericytes, and the end-feet
Abbreviations: BBB, blood-brain barrier; CBX, carbenoxolone disodium salt; CMEM,
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of astrocytes [5,6]. Recent data, however, revealed that tumor cells
growing in the brain parenchyma release vascular endothelial growth
factor and other cytokines that lead to increased vessel permeability
[7–9]. Taken together with clinical observations that brain metastases
in patients are often diagnosed as lesions surrounded by edema and
exhibit leakiness of contrast material, these data rule out the BBB as a
sole mechanism of drug resistance. Overexpression of P-glycoprotein
by tumor cells growing in the brain microenvironment [10] has also
been implicated in tumor cell resistance to chemotherapy. Clinical
trials using inhibitors of P-glycoprotein expression, however, failed
to reverse the resistance of tumor cells to chemotherapeutic drugs
or increase the response rate [1]. Collectively, these data raise the pos-
sibility that alternate as-yet-unidentified mechanisms underlie the
drug resistance of brain metastasis.
The outcome of metastasis in general and brain metastasis in par-
ticular depends on the interaction of specific metastatic cells with
host factors in the microenvironment [11]. Histologic examinations
of clinical specimens of human brain metastases and experimental
murine brain metastases reveal that the lesions are surrounded and
infiltrated by reactivated astrocytes that express glial fibrillary acidic
protein (GFAP) (Figure 1A). Astrocytes contribute to cerebral ho-
meostasis by supporting the BBB [5,12], modulating cerebral blood
flow [13,14], regulating the response of the central nervous system to
inflammation, and participating in synaptic transmission [15], cyto-
solic calcium–mediated astrocytic-neuronal signaling [16], and neuro-
vascular coupling [17]. Astrocytes have also been shown to control
extracellular homeostasis, such as ion concentration, glucose level,
acid-base balance, and supply of metabolic substances to neurons
[14,18]. Astrocytes also support immune defense in the brain and
protect neuronal cells from waste products [19,20] and damage from
hypoxia [21]. Thus, astrocytes protect neurons from alterations in
homeostasis. Because metastases develop when tumor cells exploit
or usurp the homeostatic mechanisms of their host [11], we became
intrigued by the possibility that tumor cells can exploit the cyto-
protective properties of astrocytes for protection from apoptosis in-
duced by chemotherapeutic drugs. We have recently reported that, in
culture, reactive mouse astrocytes can protect melanoma cells from
chemotherapy by sequestering intracellular calcium through gap junc-
tion communication channels. These data suggested that tumor cells
growing in the brain could harness the protective effects of reactive
astrocytes for their own survival [22].
In the current study, we explored whether a direct contact of tu-
mor cells with astrocytes also increases expression of survival genes
in the tumor cells. To test this hypothesis, we evaluated the effect
of different chemotherapeutics on tumor cells cultured alone, with
astrocytes, or with fibroblasts and assayed gene expression in these
tumor cells. We also verified the functional correlation of genes iden-
tified with protection of tumor cells from taxol by knocking down
genes using small interfering RNA (siRNA). We found that astro-
cytes (but not fibroblasts) in direct cell-to-cell contact with tumor
cells protect the tumor cells from apoptosis induced by different che-
motherapeutic drugs and that this protection is directly correlated
with the up-regulation of several survival genes in the tumor cells.
Materials and Methods
Antibodies and Reagents
Antibodies against MAPK, phospho-MAPK (Thr-202 and Tyr-204
phosphorylated), AKT, phospho-AKT (Ser-473 phosphorylated),
TWIST1, BCL2L1, and Myc were purchased from Cell Signaling
Technology (Beverly, MA). Glutathione S -transferase A5 (GSTA5)
antibody was purchased from Novus Biologicals (Littleton, CO).
β-Actin (cone AC-15) antibody was purchased from Sigma-Aldrich
(St Louis, MO), and AKTsignal transduction inhibitors (AKT inhibitor,
Figure 1. (A) Immunohistochemical analysis of mouse Lewis lung
carcinoma (3LL) in the brain of a C57BL/6 mouse. Dividing 3LL
cells (PCNA+, blue) are infiltrated and surrounded by activated as-
trocytes (GFAP+, brown). (B) Immunofluorescent staining of ex-
perimental brain metastasis produced by intracarotid injection of
human lung adenocarcinoma PC14Br4 cells into nude mouse. Ac-
tivated astrocytes were stained with GFAP polyclonal antibody
(red) and nuclei were stained with SYTOX green. Tumor cells (large
nuclei) are surrounded by activated astrocytes. (C) Scanning elec-
tron microscopy of in vitro culture of human breast cancer MDA-
MB-231 cells (T) surrounding a murine astrocyte (A). Note astrocyte
end-feet touching tumor cells.
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AKT inhibitor V/Triciribine, and MAPK inhibitors, U0126) were
purchased from Calbiochem (San Diego, CA). Carbenoxolone di-
sodium salt (CBX), a gap junction channel (GJC) inhibitor, was pur-
chased from Sigma-Aldrich. All of the chemicals were dissolved in
dimethyl sulfoxide, and all other reagents were analytical reagent
grade or better.
Immunofluorescent Analysis of Brain Metastasis
Experimental brain metastases were produced by the injection of
human lung adenocarcinoma cells PC14Br4 into the internal carotid
artery of nude mice [23]. Mice were killed 4 weeks later, and tissue
samples were processed in OCT compound for frozen section as pre-
viously described [24]. Tissues were sectioned (8-10 μm), mounted
on positively charged slides, and air-dried for 30 minutes. Tissue fix-
ation was performed using a protocol consisting of three sequential
immersions in ice-cold solutions of acetone, 50:50 (vol/vol) acetone-
chloroform, and acetone (5 minutes each). Samples were then washed
three times with phosphate-buffered saline (PBS), incubated with
protein-blocking solution containing 5% normal horse serum and
1% normal goat serum in PBS for 20 minutes at room temperature,
and then incubated with a 1:400 dilution of rabbit anti-GFAP poly-
clonal antibody (Biocare Medical, Concord, CA) for 18 hours at 4°C.
The samples were rinsed four times with PBS for 3 minutes each and
then incubated for 1 hour with a 1:1500 dilution of goat antirabbit
Cy5 antibody ( Jackson ImmunoResearch Laboratories, West Grove,
PA). Control samples were labeled with an identical concentration
of isotype control antibody and goat antirabbit Cy5 antibody. All
samples were rinsed and then briefly incubated with SYTOX green
nucleic acid stain (Eugene, OR). The slides were mounted with a
glycerol/PBS solution containing 0.1 M propyl gallate (Sigma) to min-
imize fluorescent bleaching. Confocal images were collected on a
Zeiss LSM 510 laser scanning microscope system (Carl Zeiss, Inc,
Thornwood, NY) equipped with a motorized Axioplan microscope,
argon laser, HeNe laser, LSM 510 control and image acquisition soft-
ware, and appropriate filters (Chroma Technology Corp, Brattleboro,
VT). Composite images were assembled with Photoshop software
(Adobe Systems, Inc, Mountain View, CA).
Frozen sections of clinical specimens of metastatic lung cancer
to the brain and breast cancer to the brain and lung were processed
as described above. Slides were hybridized with rabbit polyclonal
antibody against BCL2L1 (1:200; Cell Signaling), rabbit polyclonal
antibody against TWIST1 (1:200; Cell Signaling), or mouse mono-
clonal antibody against GSTA5 (1:200; Novus Biologicals). Fluores-
cein isothiocyanate–conjugated goat antimouse immunoglobulin G
(1:800; Jackson ImmunoResearch Laboratories, Inc) or Alexa Fluor
488 goat antirabbit immunoglobulin G (1:800; Molecular Probes,
Carlsbad, CA) were used for the secondary antibody. Nuclei were
visualized with 4′,6-diamidino-2-phenylindole (Vector Laboratories,
Inc, Burlingame, CA). Images were captured by an Olympus BX-51
microscope (Olympus Imaging America, Inc, Center Valley, PA) with
a DP-72 digital camera.
Immunohistochemical Analyses of Brain Metastasis
Formalin-fixed paraffin sections of experimental metastatic C57BL/
6 mouse lung cancer (3LL) cells to the brain were processed for double
staining with mouse anti–proliferating cell nuclear antigen (PCNA)
clone PC-10 (1:200; DAKO A/S, Copenhagen, Denmark) antibody
and rabbit anti-GFAP polyclonal antibody (1:400; Biocare Medical,
Concord, CA). PCNA-positive cells were visualized using a Ferangi
Blue Chromogen Kit (Biocare Medical) as blue and GFAP-positive
cells were detected by stable 3′,3′-diaminobenzidine (Research Ge-
netics, Huntsville, AL) as brown. Images were captured by Olympus
BX-51 microscopy with a DP-72 digital camera.
Cell Lines and Culture Conditions
Human breast cancer cell line MDA-MB-231, a brain metastatic
variant of human lung adenocarcinoma cell line PC14Br4, and mu-
rine NIH 3T3 fibroblasts were maintained as monolayer cultures in a
complete Eagle minimum essential medium (CMEM) supplemented
with 10% fetal bovine serum (HyClone, Logan, UT), L-glutamine
pyruvate, nonessential amino acids, two-fold vitamin solution, and
penicillin-streptomycin (GIBCO/Invitrogen, Carlsbad, CA). All re-
agents used for tissue culture were free of endotoxin as determined
by the limulus amebocyte lysate assay (Associate of Cape Cod, Woods
Hole, MA), and the cell lines were free of the following murine patho-
gens: Mycoplasma spp, Hantan virus, hepatitis virus, minute virus,
adenovirus (MAD1, MAD2), cytomegalovirus, ectromelia virus, lac-
tate dehydrogenase–elevating virus, polyma virus, and Sendai virus (as-
sayed by the Research Animal Diagnostic Laboratory, University of
Missouri, Columbia, MO). Cells used in this study were from frozen
stock, and all experiments were carried out within 10 in vitro passages
after thawing.
Isolation and Maintenance of Murine Astrocytes
Murine astrocytes were isolated from neonatal mice homozygous
for a temperature-sensitive SV40 large Tantigen (H-2K b-tsA58 mice;
CBA/ca × C57BL/10 hybrid; Charles River Laboratories, Wilmington,
MA) and established in culture in our laboratory as described in detail
previously [25].
In Vitro Coculture Chemoprotection Assay
To determine whether murine astrocytes can induce resistance of
tumor cells to chemotherapeutic agents, we performed several in vitro
chemoprotection assays. Astrocytes and NIH 3T3 fibroblasts were
transfected with GFP genes as previously described [26,27]. Target tu-
mor cells, astrocytes, or 3T3 fibroblasts were harvested from a 60%
to 70% confluent culture by a brief (2-minute) exposure to 0.25%
trypsin in a 0.1% EDTA/PBS solution. The cells were dislodged by
tapping the culture flasks briskly and resuspended in CMEM. The
murine astrocytes, 3T3 fibroblasts, and tumor cells were plated alone
or as cocultures at a tumor cell/astrocyte/3T3 cell ratio of 1:2 onto
each of the 35-mm-diameter well of the sterile six-well tissue culture
multiwell dish. The cells were allowed to adhere overnight in a humid-
ified 37°C incubator in an atmosphere of 6.4% CO2 plus air. The
cultures were then washed and incubated with fresh CMEM (negative
control) or medium containing various concentrations of taxol (Pacli-
taxel; NDC 0015-3476-30, Bristol-Myers Squibb, Princeton, NJ) and
other chemotherapeutic drugs (see below). After 72 hours, the GFP-
labeled astrocytes or NIH 3T3 cells were sorted out, and the apoptotic
fraction of tumor cells was determined by propidium iodide (PI) stain-
ing and FACS analysis (see below).
To determine whether direct contact between tumor cells and astro-
cytes (or fibroblasts serving as control) was a prerequisite to produce
induction of resistance to chemotherapy, we performed the coculture
assay using a Transwell-Boyden Chamber, i.e., plating the human tu-
mor cells in the chamber and the mouse astrocytes (or mouse fibro-
blasts) in the well. After 72 hours of incubation, the apoptotic index of
the tumor cells was determined as described below.
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To determine whether the induction of tumor cell resistance to che-
motherapywas associatedwith inhibition of P-glycoprotein, we cultured
tumor cells alone or with astrocytes (or control 3T3 fibroblasts) at the
1:2 ratio in medium containing either P-glycoprotein–associated drugs,
such as taxol (Bristol-Myers Squibb; 5 ng/ml), adriamycin (Pharmacia
andUpjohn, Kalamazoo,MI; 200 ng/ml), vinblastine (Sigma; 3 ng/ml),
or vincristine (Sigma; 8 ng/ml); or P-glycoprotein–dissociated chemo-
therapeutic agents, such as 5-FU (Sigma; 500 ng/ml) or cisplatinum
(2.4 μg/ml; SICOR Pharmaceuticals, Inc, Irvine, CA). After 72 hours
of incubation, the apoptotic index of the tumor cells was determined
as described below.
To determine whether astrocyte-mediated protection of tumor
cells occurred through GJC, we carried out the cytotoxicity assay
in the presence of CBX, a specific inhibitor of GJCs [28,29]. The
tumor cells were pretreated for 2 hours with 100 μM CBX and then
cocultured with astrocytes or fibroblasts in the presence or absence of
5 ng/ml taxol. The apoptotic index of tumor cells was determined as
described below.
In the last set of in vitro studies, we determined whether astrocyte-
mediated induction of tumor cell resistance to chemotherapeutic
drugs was transient or permanent. Human lung cancer PC14Br4 cells
were cocultured with either astrocytes or 3T3 fibroblasts in medium
alone or medium containing 5 ng/ml taxol. After 72 hours, the astro-
cytes or 3T3 cells were separated from tumor cells by FACS, and the
apoptotic index of the tumor cells was determined in multiple wells
by PI staining as described below. From parallel wells, we harvested
surviving tumor cells and replated them on monolayers of astrocytes
or 3T3 cells. These cocultures were of tumor cells first cocultured
with astrocytes and then with either astrocytes or 3T3 cells or of tu-
mor cells first cultured with 3T3 cells and then with either 3T3 cells
or astrocytes. The second round of cocultures then received medium
containing 5 ng/ml of taxol. After 72 hours, the apoptotic index of
tumor cells was determined by PI staining and FACS analysis as de-
scribed below.
Preparation for PI Staining and FACS Analysis
The supernatant medium containing floating cells was collected
from each dish into a 15-ml conical centrifuge tube. The attached
cells were harvested by briefly exposing the cells to 0.25% trypsin in
a solution containing 0.1% EDTA/PBS. Cells were combined with
the corresponding supernatant. The samples were pelleted by centri-
fugation at 100g for 5 minutes. The pellets were resuspended in 10 ml
of Hank’s balanced salt solution and further pelleted at 100g for
5 minutes. The samples were resuspended by vortexing, and the cells
were fixed in 1 ml of 1% paraformaldehyde for 10 minutes at room
temperature. The samples were then transferred into polypropylene
microcentrifuge tubes, and the fixed cells were washed in 1 ml of
PBS and then pelleted at 10,000g for 1 minute. The pellets were
resuspended by vortexing, and the cells fixed overnight in 1 ml of
ethanol at −20°C. The cells were again vortexed and pelleted in a
microcentrifuge at 10,000g for 1 minute. The samples were again
vortexed, and the pellets resuspended and stained in 300 μl of PI
(50 μg/ml; Cat. P4864; Sigma) containing RNAse (15 μg/ml; Cat.
A7973; Promega, Madison, WI) for 20 to 30 minutes at 37°C. The
samples were finally transferred to 5-ml plastic culture tubes for FACS
analysis using a Coulter EPICS Cytometer (Beckman Coulter, Inc,
Fullerton, CA). The apoptotic index was determined by comparing
the apoptotic index of tumor cells/apoptotic index of tumor cells
and astrocytes or tumor cells and NIH 3T3 fibroblasts × 100 [30].
Values are the mean ± SD of triplicate experiments, and the figures
represent three independent experiments.
MTT Assay
Five thousand MDA-MB-231 cells were mixed with an equal
number of astrocytes and seeded in 38-mm2 wells of flat-bottomed
96-well plates in triplicate and allowed to adhere overnight. The cul-
tures were then washed and refed with medium (negative control) or
medium containing various concentrations of vinblastine to include
the peak plasma level or the drug at 1 μg/ml. After 96 hours, the anti-
proliferative activity was determined by the MTT assay [31], which
monitors the number of metabolically active cells. After a 2-hour in-
cubation in medium containing 0.42 mg/ml MTT, the cells were
lysed in 100 μl of dimethyl sulfoxide. The conversion of MTT to for-
mazan by metabolically active viable cells was monitored by a CERES
UV900C 96-well microtiter plate scanner at 570 nm (BioTek Instru-
ments, Inc, Winooski, VT). The absorbance of astrocytes treated with
vinblastine was used for background subtraction to derive the survival
fraction of the MDA-MB-231 from the cocultured values. Percent
cytotoxicity was calculated from the following formula: cytotoxic-
ity (%) = (1 − A / B) × 100, where A is the absorbance of treated cells
and B is the absorbance of the control cells.
Scanning Electron Microscope Imaging of Cultured Tumor
Cells and Astrocytes
Cocultured tumor cells and astrocytes were imaged by scanning
electron microscope as previously described with modifications [32].
Detailed experimental procedure is described in the supplemental
experimental procedure.
Communication through GJC
Gap junction communication between recipient tumor cells (MDA-
MB-231) and donor cells (astrocytes, 3T3 cells, MDA-MB-231) was
analyzed by flow cytometry measuring the transfer of dye. Briefly, re-
cipient cells (300,000 cells per well) were plated into a six-well plate
and cultured overnight. At that time, donor cells were labeled for
45 minutes with 1 μg/ml green calcein-AM (Molecular Probes) fol-
lowed by extensive washing. Donor cells (60,000 cells/well) were cocul-
tured for 5 hours with recipient cells either directly or in a Transwell
chamber (Transwell-Boyden Chamber, 0.4-μm pore size; Costar,
Corning, NY). Cells were harvested, washed, fixed in ethanol, and
analyzed by flow cytometry. Gap junction communication was repre-
sented as the percentage of the fluorescein isothiocyanate peak that
had shifted [33–36].
Gene Expression Profiles by RNA Microarray Analysis
In the first set of gene expression experiments, MDA-MB-231 or
PC14Br4 cells were incubated alone, with murine astrocytes, or with
NIH 3T3 fibroblasts in a 35-mm-diameter six-well plate (Cat. 353046;
BD Falcon, San Jose, CA). The ratio of tumor cells to murine astro-
cytes or NIH 3T3 cells was set at 1:2. After 72 hours, GFP-labeled
murine astrocytes or fibroblasts were sorted out by FACS, and the
tumor cells were processed for microarray analyses. In the second set
of experiments, we determined whether the expression of genes associ-
ated with tumor cell resistance to chemotherapeutic drugs was depen-
dent on continuous contact with astrocytes. MDA-MB-231 or PC14Br4
cells were cocultured with either murine astrocytes or NIH 3T3 cells
for 72 hours. The murine astrocytes or NIH 3T3 cells were sorted
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out, and tumor cells were either processed to determine gene expres-
sion profiles by microarray analyses or plated for a second round of
coculture with either murine astrocytes or fibroblasts. Thus, tumor
cells first cultured with murine astrocytes were cocultured again with
murine astrocytes or with fibroblasts, and conversely, tumor cells ini-
tially cultured with fibroblasts were cocultured again with fibroblasts
or astrocytes. After a 72-hour incubation, murine astrocytes or fibro-
blasts were sorted out, and the tumor cells were processed for micro-
array analyses.
For microarray analyses, total RNA (500 ng) were used for labeling
and hybridization according to the manufacturer’s protocols (Illumina,
Inc, San Diego, CA) using Illumina’s Sentrix human 6-v2 Expression
BeadChips. The BeadChips were scanned with Illumina BeadArray
Reader (Illumina, Inc). The results of microarray data were extracted
with Bead Studio 3.7 (Illumina, Inc.) without any normalization or
background subtraction. Gene expression data were normalized using
quantile normalization method in LIMMA package in R (www.r-
project.org) [37]. The expression level of each gene was transformed
into a log2 before further analysis. To select genes that were differ-
entially expressed in two culture groups, we used a class comparison
tool in BRB array tools (v3.6; Biometrics Research Branch, National
Cancer Institute, Bethesda, MD) as a method for two-sample t-test
with the estimation of false discovery rate. To avoid potential false-
positive genes because of technical variance, all experiments were car-
ried out in quadruplicate.
Western Blot Analysis
Western blot analysis was used to confirm the results of the micro-
array. Briefly, whole-cell lysates of FACS-sorted tumor cells were pre-
pared using 1 ml of lysis buffer (10 mM Tris [pH 8.0], 1 mM EDTA,
0.1% SDS, 1% deoxycholate, 1% NP40, 0.14 M NaCl, 1 μg/ml leu-
peptin, 1 μg/ml aprotinin, and 1 μg/ml pepstatin) containing a pro-
tease inhibitor mixture (Roche, Indianapolis, IN). Samples containing
equal amounts of protein (30 μg) were separated by electrophoresis on
4% to 12% Nu-PAGE gels (Invitrogen) and transferred to nitrocellu-
lose membranes. After blocking with TBS + 0.1% Tween 20 contain-
ing 5% nonfat milk, the membranes were incubated at 4°C overnight
with primary antibodies (1:1000). Blots were then exposed to horse-
radish peroxidase–conjugated secondary antibodies (1:3000) and visu-
alized by the enhanced chemiluminescence system from Amersham
(Piscataway, NJ). To ensure equal protein loading, we stripped the
blots and reprobed with an anti–β-actin antibody.
Knockdown and Overexpression of BCL2L1, GSTA5,
and TWIST1
Small interfering RNA. RNA interferencewas performed onMDA-
MB-231 cells by using Lipofectamine 2000 (Invitrogen) following
themanufacturer’s instructions. For silencing target proteins, SMART-
pool-sequenced siRNA targeting BCL2L1 (NM_001191), GSTA5
(NM_153699), TWIST1 (NM_000474), and nonspecific control
pool (negative control) were purchased from Dharmacon Research
(Lafayette, CO). siRNA oligos were diluted in RNAse-free solution
and sorted at −80°C. MDA-MB-231 cells of 50% to 60% confluency
were transfected with the final concentration of 100 nM siRNA or
the nonspecific control siRNA pool. Knockdown of target proteins
was confirmed by Western blot using whole-cell lysates prepared
72 hours after transfection.
Overexpression. Myc-tagged ORF clones of BCL2L1, GSTA5, and
TWIST1 were purchased from OriGene Technologies (Rockville,
MD). MDA-MB-231 cells of 80% to 90% confluency were trans-
fected with 10 μg of plasmid of a single gene or a pool of three genes
by using Lipofectamine 2000 (Invitrogen) following the manufac-
turer’s instructions. Ten micrograms of pCMV6 plasmid was used
as a negative control. Overexpression of target proteins was con-
firmed by Western blot at various time points.
For chemoprotection assay, tumor cells transfected with siRNA or
Myc-tagged target proteins were harvested 12 hours after transfec-
tion. Tumor cells were cultured alone, with GFP-murine astrocytes,
or with GFP-3T3 cells for 72 hours. Tumor cells were collected by
sorting out GFP-murine astrocytes or GFP-3T3 cells, and then the
apoptotic fraction of tumor cells was determined by PI staining and
FACS analysis as described in the In Vitro Coculture Chemoprotec-
tion Assay section.
Western Blot Analysis for Expression of AKT/pAKT and
MAPK/pMAPK in Human Breast Cancer Cells and Lung
Cancer Cells Cultured Alone or Cocultured with Astrocytes
or Fibroblasts
Because expression of BCL2L1 and TWIST1 has been reported to
be related to activated AKT and MAPK pathways leading to anti-
apoptosis and survival of the cells and GSTA5 was related to drug
resistance, Western blot analyses were performed for expression of
phosphorylated AKT and phosphorylated MAPK. Tumor cells were
cocultured for 72 hours with GFP-labeled astrocytes or fibroblasts.
The tumor cells were then collected by FACS. Whole-cell lysates
were prepared, and equal amounts of proteins were subjected to
Western blot analysis with the indicated antibodies.
Determination of the Role of Survival Genes BCL2L1,
GSTA5, and TWIST1 in AKT and MAPK Activation and
the Role of AKT and MAPK Activation in the Regulation
of BCL2L1, GSTA5, and TWIST1 Gene Expression
In the first set of experiments, siRNA of nonspecific (NS-siRNA)
and combined siRNA (mixed siRNA) were transfected to MDA-
MB-231 and PC14Br4 cells. Twelve hours after the transfection, the
tumor cells were cultured alone and cocultured with murine astrocytes
or fibroblasts. Whole tumor cell lysates were prepared as described. Pro-
teins were subjected to Western blot analysis with indicated antibodies.
In the second set of experiments, MDA-MB-231 and PC14Br4 cells
were preincubated for 2 hours with AKT inhibitor (10 μM AKT in-
hibitor V/Triciribine) and MAPK inhibitor (10 μM U0126) and then
cultured for 72 hours alone or cocultured with murine astrocytes or
fibroblasts. Whole-cell lysates of tumor cells were prepared and sub-
jected to Western blot analysis using the indicated antibodies.
Statistical Analysis
The apoptotic index was compared by the Student’s t test. For sta-
tistical analysis of gene expression profiles, the expression level of each
gene was transformed into a log2 before further analysis. Class compar-
ison tool in BRB Array Tools (v3.6; Biometrics Research Branch, Na-
tional Cancer Institute) for a two-sample t test with the estimation of
false discovery rate was the method used to determine the statistical
significance of differentially expressed genes between tumor cells co-
cultured with different host cells. Genes for Venn diagram analysis
were selected by univariate test (two-sample t test) with multivariate
permutation test (10,000 random permutations). We applied a cutoff
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P value < 0.001 to retain genes whose expressions were significantly
different between the two groups of tissues examined.
Results
Astrocyte-Tumor Cell Interactions
As shown in Figure 1A, mouse lung cancer (3LL) cells (blue) grow-
ing in the brain of syngeneic C57BL/6 mouse are surrounded and in-
filtrated by GFAP-positive (brown) astrocytes. In Figure 1B, PC14Br4
human lung cancer cells (green) growing in the brain of a nude mouse
are surrounded and infiltrated by GFAP-positive (red) murine astro-
cytes. In Figure 1C , a scanning electron microscopy of in vitro cul-
tured human MDA-MB-231 breast cancer cells (T) and murine
astrocytes (A) demonstrates direct contact between the astrocytes (ex-
tending end-feet) and tumor cells. As clearly shown, a single astro-
cyte could be in direct contact with multiple tumor cells. Thus, the
astrocyte-tumor interactions are evident from both cell cultures and
in vivo animal experiments.
Astrocytes Protect Tumor Cells from Toxicity of
Chemotherapeutic Drugs
Culturing of human MDA-MB-231 breast cancer cells or human
PC14Br4 lung cancer cells with astrocytes (but not 3T3 fibroblasts)
reduced the apoptotic index (increased resistance) of tumor cells in-
cubated for 72 hours with taxol (5 ng/ml) by 58.3% ± 8.9% (mean ±
SD, P < .01) and 61.8% ± 6.7% (mean ± SD, P < .05), respectively.
When tumor cells and astrocytes were separated by a semipermeable
membrane (Transwell-Boyden Chamber, 0.4-μm pore size mem-
brane; Costar), the protective effect was not observed. Coculture of
tumor cells with 3T3 fibroblasts did not protect tumor cells from
chemotherapy (Figure 2A). Similarly, coculture of human tumor cells
with fibroblasts isolated from the H-2kb-tsA58 mouse did not protect
the tumor cells from treatment with different chemotherapeutic
drugs (data not shown). Thus, we conclude that this reduction was
dependent on direct contact between tumor cells and astrocytes.
In the next set of experiments, we ruled out the possibility that the
astrocyte-mediated protection of tumor cells from taxol was due to
P-glycoprotein. Human lung cancer PC14Br4 cells were cultured alone
or with astrocytes (1:2 ratio) for 72 hours in medium containing var-
ious chemotherapeutic drugs. The astrocytes protected PC14Br4 cells
against chemotherapeutic agents that can be excluded from the cell
by P-glycoprotein, such as adriamycin (P < .05), taxol (P < .05), vin-
blastine (P < .01), and vincristine (P < .01), and agents that are unre-
lated to P-glycoprotein, such as 5-FU (P < .01) and cisplatinum (P <
.01) (Figure 2B). Astrocytes protected tumor cells from both types of
agents, so we conclude that the protection mechanism was unrelated
to P-glycoprotein.
We next evaluated the astrocyte-mediated chemoprotection by an-
other assay, i.e., the MTT assay. Human MDA-MB-231 cells were
cocultured with astrocytes in medium containing different concen-
trations of vinblastine. Here again, the data shown in Figure 2C
demonstrate significant (P < .01) protection of tumor cells by the
astrocytes. Together, the results suggest that astrocytes protect tumor
cells from cytotoxic killing by chemotherapeutic drugs.
GJC of Astrocytes But Not 3T3 Cells Are Involved in
Contact-Mediated Protection of Tumor Cells
GJCs have been shown to be involved in the transmission of apop-
totic and survival signals between neighboring cells [36,38]. Transfer of
Figure 2. Chemoprotection assay by PI staining and FACS analysis
(A, B) or MTT assay (C). (A) Note the significant (P < .01) decrease
in apoptotic index in tumor cells directly cocultured with astro-
cytes but not in those cocultured with fibroblasts. Separating
the tumor cells from astrocytes with a 0.4-μm pore membrane
prevented induction of chemoprotection. (B) Astrocyte-mediated
chemoprotection against different chemotherapeutic drugs. Cocul-
ture of human lung cancer cell PC14Br4 with astrocytes induced
significant protection against all P-glycoprotein–dissociated drugs.
(C) Astrocyte protection of tumor cells from vinblastine measured
by MTT assay. At various concentrations of vinblastine, coculture
of human breast cancer cell MDA-MB-231 with astrocytes induced
significant protection (P < .01).
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the dye clearly occurred between astrocyte-tumor cell cultures in di-
rect contact but did not occur for those cells which were separated
by the membrane of the Transwell system (Figure 3A).
Similar results were seen for tumor and fibroblast cells or tumor and
tumor cells, suggesting that GJCs were able to transfer green calcein-
AM dye from donor, including astrocytes, 3T3 cells, or PC14Br4
tumor cells to recipient PC14Br4 tumor cells. To determine whether
astrocyte-mediated protection of tumor cells occurred through GJC,
we carried out the cytotoxicity assay in the presence of CBX, a specific
inhibitor of GJC channels [28,29]. CBX (100 μM) was not toxic to
any of the cells tested (data not shown). Control astrocytes, but not
fibroblasts, protected the MDA-MB-231 cells (35.5 ± 1.5 vs 20.0 ±
3.7, P < .01, and 35.5 ± 1.5 vs 37.4 ± 0.3, P > .05) (Figure 3B)
and PC14Br4 cells (38.2 ± 0.2 vs 20.0 ± 0.8, P < .01, and 38.2 ±
0.2 vs 34.0 ± 2.1, P > .05) (Figure 3C) from taxol. However, treatment
with CBX completely reversed the protection (33.4 ± 3.3 vs 30.8 ±
3.1, P > .05 [Figure 3B] and 45.3 ± 0.7 vs 41.6 ± 0.7, P > .05
[Figure 3C ]). The results suggest that GJCs of astrocytes but not
3T3 cells are involved in contact-mediated protection of tumor cells.
Pattern of Gene Expression in Tumor Cells Cocultured
with Astrocytes
To identify cancer cell genes whose expressions were altered only
on interaction with astrocytes, human-specific gene expression data
from human cancer cells cocultured with murine astrocytes were
compared with human-specific gene expression data obtained from
cancer cells cocultured with fibroblasts or cultured alone. The data
shown in Figure 4A demonstrate that human and mouse genes could
be clearly differentiated.
Because the coculture of murine astrocytes (but not murine fibro-
blasts) with tumor cells led to increased resistance of both human
breast cancer MDA-MB-231 and human lung cancer PC14Br4 cells
to chemotherapy, we sought to identify tumor cell genes whose ex-
pressions were commonly altered subsequent to coculture with astro-
cytes by applying two-sample t tests (P < .001). Using this procedure,
we found that in the MDA-MB-231 cells, 1069 genes, and in the
PC14Br4 cells, 594 genes were differentially expressed. A two-gene
list comparison revealed increased expression of several genes well
known to be associated with drug resistance, antiapoptosis, and sur-
vival, such as GSTA5, BCL2L1, and TWIST1 (Figure 4B). The ex-
pression of other multidrug resistance genes or survival genes was not
elevated in the described high stringent condition. The expression of
these genes was confirmed at the protein level by Western blot anal-
ysis of cultured cells (Figure 4C ) and by immunofluorescent analyses
of clinical specimens of breast and lung cancer brain metastases (Fig-
ure 4D). Examination of clinical specimen of breast cancer metasta-
ses to the lung did not reveal expression of BCL2L1, TWIST1, and
GSTA5 (Figure 4D). These data demonstrate the unique feature of
the brain microenvironment.
Next, we determined whether the altered gene expression pattern
in tumor cells cocultured with astrocytes (but not fibroblasts) was
permanent or transient, i.e., is it dependent on a continuous tumor
cell contact with astrocytes? The human lung cancer PC14Br4 cells
were cocultured for 72 hours with astrocytes or fibroblasts in medium
containing taxol (5 ng/ml). Human PC14Br4 lung cancer cells cocul-
tured with astrocytes exhibited a significant decrease in apoptotic index
(increased resistance) compared with tumor cells cocultured with fibro-
blasts (30.9% ± 3.3% and 54.6% ± 0.6%, respectively, P < .01). Par-
allel cultures of tumor cells cocultured with astrocytes or fibroblasts for
72 hours were collected and then reincubated with astrocytes or fibro-
blasts for another 72 hours in medium containing 5 ng/ml taxol. Tu-
mor cells initially cocultured with astrocytes and again with astrocytes
had a significant decrease in apoptotic index compared with tumor
Figure 3. (A) Gap junction assay. Transfer of calcein AM from the
donor cells to the recipient cells was observed only when donor
cells and recipient cells were cocultured in direct contact. When
cells were cultured in Transwell system, which inhibited direct cell
contact between donor and recipient cells, gap junction was not es-
tablished between them, and consequently, calcein AM was not
transferred to the donor cells. (B and C) Effect of CBX on chemopro-
tection. Chemoprotection assay was performed by PI staining and
FACS analysis. CBX significantly reversed the protective effects in-
duced by astrocytes in MDA-MB-231 (B) and PC14Br4 (C). *P< .01.
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Figure 4. (A) Measured expression patterns of human and mouse genes by cross-species hybridization with human and mouse RNA
microarray slides. The data are presented in matrix format in which rows represent individual gene and columns represent each hybrid-
ization event. Each cell in the matrix represents the expression level of a gene feature in an individual hybridization. The red in cells
reflects measured expression levels, and intensity of color represents the magnitude of expression (log2-transformed scale). These re-
sults confirm the specificity of the analyses. (B) Expression patterns of human genes in MDA-MB-231 and PC14Br4 cocultured with
murine astrocytes or 3T3 cells. We identified genes whose expression patterns were altered on interaction with astrocytes in each cell
line by applying two-sample t tests (P < .001). In MDA-MB-231 and PC14Br4 cells, 1069 and 594 genes, respectively, were differentially
expressed. The expression of 205 genes was altered in both cell lines. Of these, several are related to antiapoptosis and cell survival. (C)
Validation of microarray by Western blot analysis. Protein was extracted from MDA-MB-231 and PC14Br4 cells after they were cultured
alone or with or murine astrocytes. The expression of the antiapoptotic survival genes BCL2L1, TWIST1, and GSTA was upregulated in
MDA-MB-231 and PC14Br4 cells cocultured with murine astrocytes. (D) Expression of BCL2L1, TWIST1, and GSTA5 in clinical specimen
of breast cancer and lung cancer metastasis in the brain and breast cancer in the brain and lung. BCL2L1, TWIST1, and GSTA5 were
highly expressed (green) on tumor cells. Nuclei were stained with 4′,6-diamidino-2-phenylindole (blue). Tumor cells in clinical specimen
of breast cancer metastases to the lung were negative for expression of these genes, whereas low expression of these genes was
detected in normal alveolar epithelial cells and alveolar macrophages.
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cells that were first cultured with astrocytes and then with 3T3 fibro-
blasts (50.3% ± 4.1% vs 83.3% ± 3.1%, P < .01). PC14Br4 lung can-
cer cells initially cocultured with fibroblasts and in the second cycle
with astrocytes also had a significant decrease in apoptotic index,
but not with fibroblasts (44.4% ± 2.5% vs 81.0% ± 2.6%, P <
.01). Tumor cells initially cocultured with fibroblasts and again with
fibroblasts were not protected from chemotherapy (control culture
80.7 ± 5.8 vs 81.0 ± 2.6, P = .896128; Figure 5A). These data clearly
demonstrate that increased tumor cell resistance to multiple chemo-
therapeutic drugs requires continuous direct contact with astrocytes.
The gene expression data from the two cycles of coculture experi-
ments indicated that the influence of the second coculture was dom-
inant in gene expression patterns of the cancer cells. Regardless of the
first coculture condition, PC14Br4 cells cocultured with astrocytes in
the second cycle exhibited a distinctive gene expression signature that
was detected in the first cycle culture experiments (high expression of
GSTA5, BCL2L1, and TWIST1), whereas cancer cells cocultured
with astrocytes in the first round lost the specific gene expression sig-
natures when they were cocultured with fibroblasts in the second
round (Figure 5B). This result parallels that of the in vitro chemopro-
tection assay and strongly indicates that the gene expression pattern
in the tumor cells depended on constant contact with the astrocytes.
RNA microarray data of human and mouse genes can be accessed at
the following sites: http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?
token=zbwtvaeeaqsgqlk&acc=GSE19179 and http://www.ncbi.nlm.
nih.gov.geo.query/acc.cgi?token=dlqntswkqsuuerm&acc=GSE26293.
Genetic Modulations of Survival Genes BCL2L1, GSTA5,
and TWIST1 in Tumor Cells Alter the Resistance of Tumor
Cells to the Chemotherapeutic Agent in Cultures with or
without Astrocytes
Specific down-regulation of corresponding protein expression by
siRNAwas confirmed byWestern blot analysis (Figure 6A). Transfection
of tumor cells with siRNA targeting BCL2L1, GSTA5, and TWIST1
alone did not affect astrocyte-mediated tumor cell protection when
exposed to taxol (Figure 6B, upper panel ); however, reversal of the
Figure 5. Chemoprotection requires constant contact with astrocytes. (A) The apoptotic index of PC14Br4 cells cultured with astrocytes
was 30.9% ± 3.3%, and with fibroblasts, it was 54.6% ± 0.6% (P > .01). Tumor cells initially cultured with astrocytes were harvested
and reincubated with astrocytes or fibroblasts in the presence of taxol for another 72 hours. Tumor cells cocultured again with astro-
cytes maintained the relative resistance to taxol compared with tumor cells cocultured (second cycle) with fibroblasts. Tumor cells
initially cultured with fibroblasts were not resistant to taxol, but if these tumor cells were then reincubated (second cycle) with astro-
cytes, they developed resistance compared with tumor cells cultured again with fibroblasts. (B) Gene expression of BCL2L1, GSTA5, and
TWIST1 was determined in PC14Br4 cells cultured with astrocytes or fibroblasts. Similar to data shown in Figure 3, the survival genes
were highly expressed in tumor cells cocultured with astrocytes but not with fibroblasts (first cycle). We harvested surviving tumor cells
and cocultured them for the second cycle with either astrocytes or fibroblasts. Once again, only tumor cells cocultured with astrocytes
(second cycle) expressed higher levels of BCL2L1, GSTA5, and TWIST1.
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protective effects of astrocytes for tumor cells from taxol could only be
achieved when the tumor cells were transfected with siRNA targeting all
three genes. Specifically, the protection from chemotherapy was still ob-
served in cells transfected with siRNA targeting only NS, only BCL2L1,
only GSTA5, or only TWIST1 (41.3 ± 0.4 vs 23.1 ± 1.1, 43.4 ± 0.7 vs
27.1 ± 0.8, 42.6 ± 0.5 vs 21.0 ± 3.1, 40.3 ± 0.5 vs 26.5 ± 1.7, and 41.2 ±
2.3 vs 27.5 ± 1.7, respectively, P < .01). In contrast, protection from che-
motherapy was reversed in cells transfected with siRNA targeting all
three genes (44.9 ± 0.3 vs 58.5 ± 3.5, P > .05) (Figure 6B, upper panel ).
In the absence of taxol, siRNA had no effect on the apoptotic index
(Figure 6B, lower panel ).
In the next set of experiments, we transfected theMDA-MB-231 cells
with BCL2L1, GSTA5, and TWIST1 genes. Tumor cells stably overex-
pressed those genes at various time points (Figure 6C ). Overexpression
Figure 6. (A) Western blot analysis for validation of knockdown of target genes using siRNA. The results demonstrate specificity of the
transfection with siRNA in the down-regulation of corresponding protein expression level. (B) Upper panel. Chemoprotection assay.
Reversal of the protection by astrocytes was achieved only when all three genes were knocked down. Lower panel. Transfection of
MDA-MD-231 human breast cancer cells with siRNA targeting BCL2L1, GSTA5, and TWIST1 did not affect the apoptosis index. (C) Stable
expression of BCL2L1, GSTA5, and TWIST1 genes. Western blot analysis using anti-Myc antibody shows stable overexpression of tar-
geted genes at the indicated time points. (D) Effects of overexpression of BCL2L1, GSTA5, and TWIST1 genes of tumor cells on che-
moprotection mediated by murine astrocytes. Overexpression of BCL2L2, GSTA5, TWIST1 alone or all three genes increased tumor cell
resistance to taxol in the absence of astrocytes (upper panel). Overexpression of single gene or pool of genes did not affect the apop-
tosis index of tumor cells in control cultures (lower panel). *P < .01.
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of a single gene or pool of genes did not affect the apoptosis index of
the tumor cells in the control cultures (Figure 6D, lower panel ). Over-
expression of BCL2L1, GSTA5, TWIST1, or a pool of these three
genes led to resistance of tumor cells from taxol in the absence of astro-
cytes (19.8 ± 0.3 vs 18.2 ± 1.2, 23.0 ± 1.2 vs 18.1 ± 2.3, 23.3 ± 0.6 vs
19.4 ± 0.4, and 27.8 ± 1.2 vs 26.5 ± 1.4, respectively, P > .05)
(Figure 6D, upper panel ). Therefore, overexpression of any one gene
was sufficient to induce resistance, but all three needed to be knocked
down to have a protective effect.
Determination of the Role of Survival Genes BCL2L1,
GSTA5, and TWIST1 in AKT and MAPK Activation and
the Role of AKT and MAPK Activation in the Regulation of
BCL2L1, GSTA5, and TWIST1 Gene Expression
The activation of AKT and MAPK pathways has been reported to
have a functional and mechanistic relationship with BCL2L1 [39,40],
TWIST1 [41,42], and GSTA5 [43] genes in drug resistance, antiapop-
tosis, and survival of tumor cells. We therefore performed Western
blot analyses for the expression of phosphorylated AKTand phosphor-
ylated MAPK. Coculture of tumor cells with astrocytes upregulated
the expression of phosphorylated AKT and phosphorylated MAPK,
whereas coculture of tumor cells with 3T3 cells did not (Figure 7A).
When we knocked down BCL2L1 or TWIST1, or GSTA5, or all three
genes, the activation of AKT or MAPK pathways was not altered
(Figure 7B). In contrast, inhibition of AKTor MAPK phosphorylation
by V/Triciribine and UO126, respectively, prevented the up-regulation
of TWIST1, BCL2L1, and GSTA5 genes (Figure 7C ). These data
clearly demonstrate that AKT and MAPK pathways are upstream of
astrocyte-mediated up-regulation of expression of BCL2L1, TWIST1,
and GSTA5 genes in tumor cells.
Discussion
Our present findings raise the intriguing possibility that in addition
to maintaining homeostasis [44], regulating neuronal activity to so-
called “neuron-astrocyte metabolic coupling” [45], and protecting
neurons from apoptosis produced by hydrogen peroxide [46], etha-
nol [19], and copper-catalyzed cysteine [17], astrocytes can also pro-
tect tumor cells from chemotherapeutic drugs. The murine astrocytes
used in our studies expressed GFAP, the major intermediate filament
protein in the central nervous system of adults [46–48]. Under a
variety of conditions, these murine astrocytes protected different
human tumor cells from cytotoxicity mediated by P-glycoprotein–
associated and P-glycoprotein–dissociated chemotherapeutic drugs.
We also demonstrated that the protection of tumor cells from che-
motherapy was contact-dependent because the effect was abrogated
when tumor cells and astrocytes were separated by a semipermeable
membrane or when tumor cell–astrocyte cultures were treated with
CBX, a specific inhibitor of GJCs [28,29]. The protection was
unique to astrocytes because fibroblasts (or other tumor cells) were
unable to provide protection. The protection of tumor cells by astro-
cytes required constant contact. Tumor cells that were first cocul-
tured with astrocytes and then cocultured with fibroblasts were no
longer protected from chemotherapy. In contrast, tumor cells initially
cocultured with fibroblasts (sensitive) and then with astrocytes be-
came more resistant to the chemotherapy. These results suggested
that the protection of tumor cells from chemotherapeutic agents
depended on constant interaction with astrocytes. We have previ-
ously reported that the protective effects by astrocytes are due to
the sequestration of calcium from the cytoplasm of tumor cells
Figure 7. (A) Western blot analysis for expression of AKT/pAKT
and MAPK/pMAPK in human breast cancer cells and lung cancer
cells cultured alone or cocultured with astrocytes or fibroblasts.
Expression of AKT and MAPK was not altered whether tumor cells
were cultured alone or cocultured with astrocytes or fibroblasts.
However, the expression of phosphorylated AKT or MAPK was up-
regulated only in tumor cells cocultured with astrocytes. (B) Deter-
mination of the role of BCL2L1, GSTA5, and TWIST1 genes in AKT
and MAPK activation. Transfection with nonspecific (NS-siRNA)
and combined siRNA (Mixed siRNA) did not affect activation of
AKT and MAPK pathways. (C) Determination of the role of AKT
and MAPK activation in the regulation of BCL2L1, GSTA5, and
TWIST1 gene expression. Inhibition of activation of the AKT and
MAPK pathways inhibited the up-regulation of the expression of
BCL2L1, GSTA5 and TWIST1 genes. All figures are representative
of one experiment of three independent experiments.
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[22]. Calcium has been shown to play a causal role in cell death [49].
Whereas the sequestration of calcium through GJC can explain the
mechanism by which astrocytes protect tumor cells from chemother-
apy, it does not rule out additional mechanisms, such as up-regulation
of survival genes in tumor cells, as shown in the current study.
The direct cell-to-cell contact between astrocytes and tumor cells
altered the pattern of gene expression in both tumor cells and astro-
cytes. The use of murine astrocytes (and murine fibroblasts as negative
control) and human tumor cells (breast, lung) allowed us to identify
the altered genes in the tumor cells. Among many genes, we found
significant up-regulation of multiple genes that regulate cell survival.
Once again, the overexpression of these genes was dependent on con-
tinuous contact between astrocytes and tumor cells. For functional
validation, the expression of BCL2L1, TWIST1, and GSTA5 was con-
firmed in clinical specimens of breast and lung cancer brain metastases.
A study to investigate the correlation of gene expression and induc-
tion of drug resistance was performed with siRNA. The role of those
genes in protection against taxol was determined by coculturing astro-
cytes with MDA-MB-231 cells. This protection could be reversed only
when the tumor cells were transfected with mixed siRNA targeting all
three genes. These data demonstrate the biologic redundancy of these
survival pathways that can be used by cells to resist cytotoxic drugs
leading to apoptosis. The up-regulation of phosphorylated AKT and
phosphorylated MAPK subsequent to coculturing of tumor cells with
astrocytes, but not with 3T3 fibroblasts, supports the conclusion that
activation of these pathways leads tumor cells to resistance, antiapop-
tosis, and survival when exposed to chemotherapeutic agents. Knock-
ing down the three survival genes did not prevent AKT and MAPK
pathways from being activated, whereas blockade of AKT and MAPK
pathway activation inhibited the up-regulation of BCL2L1, TWIST1,
and GSTA5 expression. Hence, the activation of AKT and MAPK
pathways is upstream, leading to the up-regulation of expression of sur-
vival genes in tumor cells contacting astrocytes. In any case, the in-
creased expression of GSTA5, TWIST1, and BCL2L1 in tumor cells
required constant contact with astrocytes. We base this conclusion
on the data showing that the high expression of these survival genes
in tumor cells was reduced once the tumor cells were transferred to
cultures of fibroblasts. Immunohistochemical staining of clinical spec-
imen of lung cancer and breast cancer metastases to the brain clearly
demonstrate the expression of GSTA5, TWIST1, and BCL2L1 genes in
tumor cells but not in adjacent normal brain tissue. Collectively, these
data clearly demonstrate that host cells in the organ microenvironment
influence the behavior of tumor cells [19,50] and reinforce the conten-
tion that the organ microenvironment must also be taken into consid-
eration during the design of therapy. Indeed, tumor cells are known to
exploit their host for growth and survival [11], and the role of astrocytes
in the induction of drug resistance of brain metastases provides a new
concept for the design of therapy for the most fatal aspect of cancer.
Acknowledgments
The authors thank Walter Pagel for critical editorial review and com-
ments and Lola López for expert assistance with the preparation of
the article.
References
[1] Sawaya R, Bindal R, and Lang FF (2001). Metastatic brain tumors. In Brain
Tumors. AH Kaye and EE Laws (Eds). Churchill-Livingstone, New York, NY.
pp. 999–1026.
[2] Landis SH, Murray T, Bolden S, and Wingo PA (1998). Cancer statistics, 1998.
CA Cancer J Clin 48, 6–29.
[3] Norden AD, Wen PY, and Kesari S (2005). Brain metastases. Curr Opin Neurol
18, 654–661.
[4] Palmieri D, Smith QR, Lockman PR, Bronder J, Gril B, Chambers AF, Weil RJ,
and Steeg PS (2006). Brain metastases of breast cancer. Am J Pathol 26, 139–147.
[5] Abbott N (2002). Astrocytes-endothelial interactions and blood-brain barrier
permeability. J Anat 200, 629–638.
[6] Lockman PR, Mittapalli RK, Taskar KS, Rudraraju V, Gril B, Bohn KA, Adkins
CE, Roberts A, Thorsheim HR, Gaasch JA, et al. (2010). Heterogeneous blood-
tumor barrier permeability determines drug efficacy in experimental brain me-
tastases of breast cancer. Clin Cancer Res 16, 5664–5678.
[7] Yano S, Shinohara H, Herbst RS, Kuniyasu H, Bucana CD, Ellis LM, Davis D,
McConkey DJ, and Fidler IJ (2000). Expression of vascular endothelial growth
factor is necessary but not sufficient for production and growth of brain metas-
tasis. Cancer Res 60, 4959–4967.
[8] Gerstner ER and Fine RL (2007). Increased permeability of the blood-brain
barrier to chemotherapy in metastatic brain tumors: establishing a treatment
paradigm. J Clin Oncol 25, 2306–2312.
[9] Kamoun WS, Ley CD, Farrar CT, Duyverman AM, Lahdenranta J, Lacorre DA,
Batchelor TT, di Tomaso E, Duda DG, Munn LL, et al. (2009). Edema control
by cediranib, a vascular endothelial growth factor receptor–targeted kinase in-
hibitor, prolongs survival despite persistent brain tumor growth in mice. J Clin
Oncol 27, 1–13.
[10] Cordon-Cardo C, O’Brien JP, Boccia J, Casals D, Bertino JR, and Melamed MR
(1990). Expression of the multidrug resistance gene product (P-glycoprotein) in
human normal and tumor tissues. J Histochem Cytochem 38, 1277–1287.
[11] Talmadge JE and Fidler IJ (2010). AACR centennial series: the biology of cancer
metastasis: historical perspective. Cancer Res 70, 5649–5669.
[12] Seth P and Koul N (2008). Astrocyte, the star avatar: redefined. J Biosci 33,
405–421.
[13] Koehler RC, Gebremedhin D, and Harder DR (2006). Role of astrocytes in
cerebrovascular regulation. J Appl Physiol 100, 307–317.
[14] Iadecola C and Nedergaard M (2007). Glial regulation of the cerebral microvas-
culature. Nat Neurosci 10, 1369–1376.
[15] Haydon PG and Carmignoto G (2006). Astrocyte control of synaptic transmis-
sion and neurovascular coupling. Physiol Rev 86, 1009–1031.
[16] Nedergarrd M (1994). Direct signaling from astrocytes to neurons in cultures of
mammalian brain cells. Science 263, 1768–1771.
[17] Verkhratsky A and Kirchhoff F (2007). Glutamate-mediated neuronal-glial
transmission. J Anat 210, 651–660.
[18] Gee JR and Keller JN (2005). Astrocytes: regulation of brain homeostasis via
apolipoprotein E. Int J Biochem Cell Biol 37, 1145–1150.
[19] Wang XF and Cynader MS (2001). Pyruvate released by astrocytes protects neu-
rons from copper-catalyzed cystein neurotoxocity. J Neurosci 21, 3322–3331.
[20] Faulkner JR, Herrmann JE, Woo MJ, Tansey KE, Doan NB, and Sofroniew
MV (2004). Reactive astrocytes protect tissue and preserve function after spinal
cord injury. J Neurosci 24, 2143–2155.
[21] Trendelenburg G and Dirnagl U (2005). Neuroprotective role of astrocytes in
cerebral ischemia: focus on ischemic preconditioning. Glia 51, 307–320.
[22] Lin Q, Balasubramanian K, Fan D, Kim SJ, Guo L, Wang H, Bar-Eli M, Aldape
KD, and Fidler IJ (2010). Reactive astrocytes protect melanoma cells from che-
motherapy by sequestering intracellular calcium through gap junction channels.
Neoplasia 12, 748–754.
[23] Schackert G and Fidler IJ (1988). Site-specific metastasis of mouse melanomas
and a fibrosarcoma in the brain or meninges of syngeneic animals. Cancer Res
48, 3478–3484.
[24] Kim SJ, Uehara H, Yazici S, Busby JE, Nakamura T, He J, Maya M, Logothetis
C, Mathew P, Wang X, et al. (2006). Targeting platelet-derived growth factor
receptor on endothelial cells of multidrug-resistant prostate cancer. J Natl Cancer
Inst 98, 783–793.
[25] Langley RR, Fan D, Tsan RZ, Rebhun R, He J, Kim SJ, and Fidler IJ (2004).
Activation of the platelet-derived growth factor-receptor enhances survival of
murine bone endothelial cells. Cancer Res 64, 3727–3730.
[26] Dull T, Zufferey R, Kelly M, Mandel RJ, Nguyen M, Trono D, and Naldini L
(1998). A third-generation lentivirus vector with a conditional packaging sys-
tem. J Virol 72, 8463–8471.
[27] Galipeau J, Li H, Paquin A, Sicilia F, Karpati G, and Nalbantoglu J (1999).
Vesicular stomatitis virus G pseudotyped retrovector mediates effective in vivo
suicide gene delivery in experimental brain cancer. Cancer Res 59, 2384–2394.
Neoplasia Vol. 13, No. 3, 2011 Astrocytes Upregulate Tumor Cells’ Survival Genes Kim et al. 297
[28] Goldberg GS, Moreno AP, Bechberger JF, Hearn SS, Shivers RR, MacPhee DJ,
Zhang YC, and Naus CC (1996). Evidence that disruption of connexin parti-
cle arrangements in gap junction plaques is associated with inhibition of gap
junctional communication by a glycyrrhetinic acid derivative. Exp Cell Res 222,
48–53.
[29] Guan X, Wilson S, Schlender KK, and Ruch RJ (1996). Gap-junction disas-
sembly and connexin 43 dephosphorylation induced by 18 β-glycyrrhetinic
acid. Mol Carcinog 16, 157–164.
[30] Zamai L, Canonico B, Luchetti F, Ferri P, Melloni E, Guidotti L, Cappellini A,
Cutroneo G, Vitale M, and Papa S (2001). Supravital exposure to propidium
iodide identifies apoptosis on adherent cells. Cytometry 44, 57–64.
[31] Fan D, Bucana CD, O’Brian CA, Zwelling LA, Seid C, and Fidler IJ (1990).
Enhancement of tumor cell sensitivity to adriamycin by presentation of the drug
in phosphatidylcholine-phosphatidylserine liposomes. Cancer Res 50, 3619–3626.
[32] Bucana CD, Hoyer LC, Schroit AJ, and Fidler IJ (1983). Ultrastructural studies
of the interaction between liposome-activated human blood monocytes and
allogeneic tumor cells in vitro. Am J Pathol 112, 101–111.
[33] Wade MH, Trosko JE, and Schindler M (1986). A fluorescence photobleaching
assay of gap junction-mediated communication between human cells. Science 232,
525–528.
[34] Lin JH, Weigel H, Cotrina ML, Liu S, Bueno E, Hansen AJ, Hansen TW,
Goldman S, and Nedergaard M (1998). Gap-junction–mediated propagation
and amplification of cell injury. Nat Neurosci 1, 494–500.
[35] Fonseca PC, Nihei OK, Savine W, Spray DC, and Alves LA (2006). Flow cy-
tometry analysis of gap junction–mediated cell-cell communication: advantages
and pitfalls. Cytometry 69A, 487–493.
[36] Trosko JE and Ruch RJ (2002). Gap junctions as targets for cancer chemopre-
vention and chemotherapy. Curr Drug Targets 3, 465–482.
[37] Bolstad BM, Irizarry RA, Astrand M, and Speed TP (2003). A comparison of
normalization methods for high density oligonucleotide array data based on var-
iance and bias. Bioinformatics 19, 185–193.
[38] Krysko DV, Leybaert L, Vandenabeele P, and D’Herde K (2005). Gap junc-
tions and the propagation of cell survival and cell death signals. Apoptosis 10,
459–469.
[39] Qian J, Zou Y, Rahman JS, Lu B, and Massion PP (2009). Synergy between
phosphatidylinositol 3-kinase/Akt pathway and Bcl-xL in the control of apopto-
sis in adenocarcinoma cells of the lung. Mol Cancer Ther 8, 101–109.
[40] Yu YL, Chiang YJ, Chen YC, Papetti M, Juo CG, Skoultchi AI, and Yen JJ
(2005). MAPK-mediated phosphorylation of GATA-1 promotes Bcl-xL expres-
sion and cell survival. J Biol Chem 19, 29533–29542.
[41] Cheng GZ, Chan J, Wang Q, Zhang W, Sun CD, and Wang LH (2007). Twist
transcriptionally upregulates AKT2 in breast cancer cells leading to increased
migration, invasion, and resistance to taxol. Cancer Res 67, 1979–1987.
[42] Zhang X, Wang Q, Ling MT, Wong YC, Leung SC, and Wang X (2007). Anti-
apoptotic role of TWIST and its association with Akt pathway in mediating taxol
resistance in nasopharyngeal carcinoma cells. Int J Cancer 120, 1891–1898.
[43] Kazi S and Ellis EM (2002). Expression of rat liver glutathione-S -transferase
GSTA5 in cell lines provides increased resistance to alkylating agents and toxic
aldehydes. Chem Biol Interact 20, 121–135.
[44] Volterra A and Meldolesi J (2005). Astrocytes, from brain glue to communica-
tion elements: the revolution continues. Nat Rev Neurosci 6, 626–640.
[45] Kasischke KA, Vishwasrao HD, Fisher PJ, Zipfel WR, and Webb WW (2004).
Neural activity triggers neuronal oxidative metabolism followed by astrocytic
glycolysis. Science 305, 99–103.
[46] Desagher S, Glowinski J, and Premont J (1996). Astrocytes protect neurons
from hydrogen peroxide toxicity. J Neurosci 16, 2553–2562.
[47] Sofroniew MV (2005). Reactive astrocytes in neural repair and protection.
Neuroscientist 11, 400–407.
[48] Pekny M and Nilsson M (2005). Astrocyte activation and reactive gliosis. Glia
50, 427–434.
[49] Roderick HL and Cook SJ (2008). Ca2+ signaling checkpoints in cancer: remod-
eling Ca2+ for cancer cell proliferation and survival. Nat Rev Cancer 8, 361–375.
[50] Gupta GP and Massagué J (2006). Cancer metastasis: building a framework.
Cell 127, 679–695.
298 Astrocytes Upregulate Tumor Cells’ Survival Genes Kim et al. Neoplasia Vol. 13, No. 3, 2011
